The Journal of dermatological treatmentAdolescentAdultFemaleHumansMale
Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial.
Qingchun Diao, Ruiling Jia, Min Li, Peng Zhao, Fang Lu, Qin Zhang, Chunzhu Ning, Juan Long, Jiajia Li, Yan Huang, Yuyi Wang
Published: 202510.1080/09546634.2025.2591478
Abstract
BACKGROUND: Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD). OBJECTIVE: This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients…
Preview only. Read the full abstract at the source